Meeting
2013 ASCO Annual Meeting
Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.
Authors
Yvonne M. Saenger
Mount Sinai School of Medicine, New York, NY
Yvonne M. Saenger , Jay Magidson , Bobby Chi-Hung Liaw , Karl Wassmann , William Barker , Sara Harcharik , David Fisher , William K. Oh , Philip Friedlander
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9080)
DOI
10.1200/jco.2013.31.15_suppl.9080
Abstract #
9080
Poster Bd #
49C
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study.
First Author: Anna Maria Di Giacomo
Poster
2017 ASCO Annual Meeting
The CCTG PA.7 trial: A randomized phase II study of gemcitabine and nab-paclitaxel vs. gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab as 1st line therapy in metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Daniel John Renouf
Poster
2017 ASCO Annual Meeting
A randomized phase II study of ipilimumab at 3 (ipi3) or 10 mg/kg (ipi10) alone or in combination with high dose interferon-alfa (HDI) in advanced melanoma (E3611).
First Author: Ahmad A. Tarhini
Poster
2013 ASCO Annual Meeting
Nonclinical evaluation of the combination of mouse IL-21 and anti- mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models.
First Author: Maria Jure-Kunkel